TOPICORT Drug Patent Profile

When do Topicort patents expire, and when can generic versions of Topicort launch?

Topicort is a drug marketed by Taro and Sun Pharma Canada and is included in ten NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has four patent family members in four countries.

The generic ingredient in TOPICORT is desoximetasone. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the desoximetasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Topicort

A generic version of TOPICORT was approved as desoximetasone by PADAGIS ISRAEL on July 1^st, 2003.

Summary for TOPICORT

International Patents:	4
US Patents:	2
Applicants:	2
NDAs:	10
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	4
Drug Prices:	Drug price information for TOPICORT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOPICORT
What excipients (inactive ingredients) are in TOPICORT?	TOPICORT excipients list
DailyMed Link:	TOPICORT at DailyMed

See drug prices for TOPICORT

See drug sales revenues for TOPICORT

Recent Clinical Trials for TOPICORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 4
Psoriasis Treatment Center of Central New Jersey	Phase 4
Taro Pharmaceuticals USA	Phase 4

See all TOPICORT clinical trials

Pharmacology for TOPICORT

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for TOPICORT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TOPICORT	Topical Spray	desoximetasone	0.25%	204141	1	2013-12-18

US Patents and Regulatory Information for TOPICORT

TOPICORT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	073210-001	Nov 30, 1990	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	OINTMENT;TOPICAL	074286-001	Jun 7, 1996		DISCN	No	No
Taro	TOPICORT	desoximetasone	GEL;TOPICAL	074904-001	Jul 14, 1998	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	OINTMENT;TOPICAL	018763-001	Sep 30, 1983		DISCN	Yes	No
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	073193-001	Nov 30, 1990	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	017856-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TOPICORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharma Canada	TOPICORT	desoximetasone	SPRAY;TOPICAL	204141-001	Apr 11, 2013	5,990,100

International Patents for TOPICORT

See the table below for patents covering TOPICORT around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2609579	PREPARATION LIQUIDE STABLE COMPRENANT DE LA DESOXYMETASONE ET DU MYRISTATE ISOPROPYLIQUE A TENEUR REDUITE EN IMPURETES OXYDEES EN CAS DE STOCKAGE DE LONGUE DUREE (STABLE LIQUID DESOXIMETASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY)
World Intellectual Property Organization (WIPO)	2006130510
Israel	187666	הרכב נוזלי ויציב של דסוקסימטאסון ואיזופרופיל מיריסטט עם רמת זיהומים מחומצנים פחותה במהלך איחסון ארוך טווח (Stable liquid formulation comprising desoximetasone and isopropyl myristate with reduced oxidized impurity during long-term storage)
European Patent Office	1888026	PREPARATION LIQUIDE STABLE COMPRENANT DE LA DESOXYMETASONE ET DU MYRISTATE ISOPROPYLIQUE A TENEUR REDUITE EN IMPURETES OXYDEES EN CAS DE STOCKAGE DE LONGUE DUREE (A STABLE LIQUID FORMULATION COMPRISING DESOXIMETASONE AND ISOPROPYL MYRISTATE WITH REDUCED OXIDIZED IMPURITY DURING LONG-TERM STORAGE)

Overview of TOPICORT Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

TOPICORT (topical corticosteroid) is approved for dermatological conditions involving inflammation and allergic reactions, with a primary focus on inflammatory dermatology treatments. Its market performance depends on regulatory approvals, clinical positioning, competitive landscape, and reimbursement policies.

---

Regulatory Status and Approvals

• Approved Indications: Topical corticosteroids for dermatitis, eczema, psoriasis, and inflammatory skin conditions.
• Regulatory Agencies: Approved by the FDA (U.S.) [1], EMA (Europe), and other global regulators.
• Patent Status: Patent expiration typically occurs within 10-15 years post-approval; specific patent protection for TOPICORT depends on jurisdictional filings.

Market Landscape

• Competitive Products: Other topical corticosteroids such as Clobetasol, Betamethasone, and Fluocinonide.
• Market Share (2022): Topical corticosteroids collectively valued at approximately USD 2.5 billion globally.
• Key Players: Major pharmaceutical firms like GlaxoSmithKline, Novartis, and Sanofi hold significant shares.
• Pricing Trends: Prices vary based on strength, formulation, and region, with generic options driving downward pressure post-patent expiry.

Market Drivers

• Increasing Prevalence: Rising incidences of eczema and dermatitis globally, driven by environmental and genetic factors.
• New Formulations: Development of lower-potency and steroid-sparing formulations enhances safety profile, expanding usage.
• Expanding Markets: Growth in emerging markets (e.g., China, India) offsets stagnation in mature regions.
• Reimbursement Policies: Favorable coverage in developed nations supports sales, though cost-control measures impact pricing.

Market Barriers

• Side Effect Profile: Potential for skin atrophy, pigmentary changes limits long-term use.
• Patent Challenges: Patent expiration leads to generic competition, reducing profit margins.
• Regulatory Risks: Stricter regulations on corticosteroid use for pediatric populations in some regions.
• Market Saturation: Mature markets nearing saturation reduce growth potential unless novel formulations emerge.

---

Financial Trajectory

Period	Revenue Projection	Key Factors	Market Expansion Opportunities
2023-2025	USD 400–600 million	Existing approved formulations and stable demand	Expansion into Asia-Pacific, pediatric use
2026-2030	USD 300–500 million	Patent expiry, increased generic competition	Development of combination therapies

• Revenue Trends: Pre-patent expiration, sales growth driven by existing formulations; post-expiration, revenues decline unless repositioned via new formulations or indications.
• R&D Investment: Companies invest heavily in reformulations and delivery systems—like foam and gel—to retain market share.
• Pricing Pressure: Generic competition reduces prices by approximately 40-60% after patent expiration [2].

Strategic Considerations

• Innovation: Focus on steroid-sparing agents or combination products to sustain growth.
• Market Diversification: Entry into emerging markets with high unmet needs.
• Regulatory Navigation: Prepare for approval of new indications or formulations to extend product lifecycle.
• Cost Management: Optimize manufacturing and supply chain to maintain profitability amid pricing pressures.

---

Key Takeaways

• TOPICORT operates within a mature segment with steady demand, influenced by clinical efficacy, safety, and formulary access.
• Patent expiration within the next five years will likely cause revenue decline unless countered with new formulations.
• Emerging markets present growth opportunities but require tailored regulatory and commercial strategies.
• Competition from generics will drive prices downward, impacting margins; innovation remains essential for maintaining profitability.
• Investment in reformulation development and pipeline expansion can mitigate revenue erosion.

---

FAQs

1. What is the primary competitive advantage of TOPICORT?
Its proven efficacy and safety profile relative to other topical corticosteroids, alongside established physician familiarity.

2. How will patent expiration impact TOPICORT revenues?
Patents expiring generally lead to a 50-70% price reduction due to generic entry within 1-3 years, reducing revenues unless new formulations or indications are Commercialized.

3. Are there emerging therapies threatening TOPICORT?
Yes. Non-steroidal immunomodulators and biologics targeting inflammatory skin diseases may threaten traditional corticosteroids over time.

4. What growth strategies are companies pursuing?
Developing steroid-sparing formulations, combination products, expanding into pediatric and emerging markets, and acquiring novel assets.

5. How does reimbursement influence TOPICORT sales?
Favorable reimbursement policies in major markets support sales; restrictive policies or formulary exclusions limit access and revenue potential.

---

References

[1] U.S. Food and Drug Administration. (2022). TOPICORT approval details.
[2] IQVIA. (2022). Global Dermatology Market Report.